We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most aggressive and difficult-to-treat brain cancers.
During the interview, Dr. Brenner discussed the promise of REYOBIQ™, Plus Therapeutics’ novel targeted radiation therapy, and how this innovative treatment is currently being evaluated in the RESPECT-GBM Phase 2 clinical trial. He also spoke about his team’s critical work at the Mays Cancer Center at UT Health San Antonio, one of the key research sites helping bring this investigational therapy to patients.
“We’re focused on precision therapy for glioblastoma patients who currently have very few treatment options,” said Dr. Brenner. “Through the RESPECT-GBM trial, we aim to bring new hope through a novel radiotherapeutic approach.”
Watch the full interview here:
Dr. Brenner on KABB News
Want to learn more about the RESPECT-GBM trial or see if you may qualify to participate?
Visit our official trial website for detailed information on eligibility criteria, study locations, and more:
Learn more at RESPECT-trials.com
You can also reach our team directly at respect@plustherapeutics.com for questions or referrals.
#PlusTherapeutics #RESPECTGBM #Glioblastoma #GBM #REYOBIQ #BrainCancer #CancerResearch #Oncology #ClinicalTrials #RadiationTherapy #BrainTumorStrong #PSTV #NeuroOncology #KABBNews
Recent Comments